Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1
    3.
    发明申请
    Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1 审中-公开
    可用作伤害感受肽受体ORL-1的配体的氮杂环丁烷二胺

    公开(公告)号:US20030195185A1

    公开(公告)日:2003-10-16

    申请号:US10294814

    申请日:2002-11-14

    摘要: Disclosed are nociceptin ORL-1 receptor agonists of the formula 1 wherein: (a) R1 is optionally substituted alkyl, fluorenyl, pyrimidinyl or optionally substituted piperidinyl; R2 is H; and R3 is nullC(H)(R)nullNR7R8; R is H, optionally substituted aryl or arylalkyl, or heteroaryl; R7 is null(CH2)xR9, optionally substituted tetrahydronaphthyl, or cycloalkyl; and R8 is H; or R7 and R8 together form a substituted piperidinyl or piperazinyl ring; x is 0-10; and R9 is H, alkoxy, optionally substituted phenyl, naphthyl, heteroaryl, pyrrolidinyl, pyrrolidonyl, optionally substituted piperidinyl or diphenylmethyl; or (b) R2is nullNHR7or 2 and R3 is H; pharmaceutical compositions; and methods of using the compounds to treat cough and pain.

    摘要翻译: 公开了下式的伤害感受肽ORL-1受体激动剂,其中:(a)R <下标> 1是任选取代的烷基,芴基,嘧啶基或任选取代的哌啶基; R <下标> 2 是H; 并且R <下标3 是-C(H)(R)-NR <下标> 7 R <下标> 8 ; R是H,任选取代的芳基或芳烷基或杂芳基; R <下标> 7 是 - (CH <下标> 2 )<下标> x R <下标> 9 ,任选取代的四氢萘基或环烷基; 而R 8>是H; 或R <下标7 和R <下标8 一起形成取代的哌啶基或哌嗪基环; x为0-10; 并且R <下标9是H,烷氧基,任选取代的苯基,萘基,杂芳基,吡咯烷基,吡咯烷酮基,任选取代的哌啶基或二苯基甲基; 或(b)R <下标> 2 是-NHR <下标> 7 ,或者R <下标> 3 是H; 药物组合物; 以及使用该化合物治疗咳嗽和疼痛的方法。

    Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders
    4.
    发明申请
    Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders 失效
    选择性D1 / D5受体拮抗剂用于治疗肥胖和CNS疾病

    公开(公告)号:US20040058906A1

    公开(公告)日:2004-03-25

    申请号:US10649495

    申请日:2003-08-27

    IPC分类号: A61K031/55 C07D487/02

    CPC分类号: C07D487/04 C07D513/04

    摘要: The present invention provides compounds, which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1/D5 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

    摘要翻译: 本发明提供了作为D1 / D5受体的新型拮抗剂的化合物以及制备这些化合物的方法。 在另一个实施方案中,本发明提供包含这种D1 / D5受体拮抗剂的药物组合物以及使用它们治疗CNS障碍,肥胖,代谢紊乱,进食障碍如食欲过盛和糖尿病的方法。

    Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
    5.
    发明申请
    Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity 失效
    作为选择性黑色素浓缩激素受体拮抗剂的Spirosidone哌啶用于治疗肥胖症

    公开(公告)号:US20040024002A1

    公开(公告)日:2004-02-05

    申请号:US10607051

    申请日:2003-06-26

    IPC分类号: A61K031/4747

    CPC分类号: C07D471/10

    摘要: The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

    摘要翻译: 本发明公开了作为黑色素浓缩激素(MCH)的新型拮抗剂的化合物以及这些化合物的制备方法。 在另一个实施方案中,本发明公开了包含这样的MCH拮抗剂的药物组合物以及使用它们治疗肥胖,代谢紊乱,进食障碍如食欲过盛和糖尿病的方法。